Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Atzpodien, J, Hänninen LE, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illiger H-J, Jakse G, Niesel T, Scholz H-J, Wilhelm S, Pielmeier T, Zabrewski G, Blum G, Beier J, Müller G-W, Duensing S, Anton P, Allhoff E, Jonas U and Poliwoda, H (1995) Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13: 497–501
Facendola G, Locatelli MC, Pizzocaro G, Piva L, Pegoraro C, Bobbio Pallavicini E, Signaroldi A, Meregalli M, Lombaardi F, Beretta GD, Scanzi F, Labianca R and Luporini G (1995) Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. Br J Cancer 72: 1531–1535
Huland E and Huland, H (1989) Locla continuous high-dose interleukin-2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49: 5469–5474
Ljungberg B and Henriksson, R (1997) Immunotherapy of metastatic renal cell carcinoma. Curr Opin Urol 7: 252–258
Philip T, Negrier S, Lasset C, Coronel B, Bret M, Baly JY, Merrouche Y, Carrie C, Kaemmerlein P, Chauvin F, Favrot M, Oskam R, Tabah I, Clavel M, Moskovtchenko JF and Mercatello A (1993) Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institutional study on 181 patients. Br J Cancer 68: 1036–1042
Steinec G, Strander, H, Carbin B-E, Borgström E, Wallin L, Achtnich U, Arvidsson A, Söderlund V, Näslund I, Esposti P-L and Norell SE (1990) Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 29: 155–162
Wagstaff J, Baars JW, Wobink G-J, Hoekman K, Eerenberg-Belmer AJM and Hack CE (1995) Renal cell carcinoma and interleukin-2. A review. Eur J Cancer 31A: 401–408
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply. Br J Cancer 82, 246–247 (2000). https://doi.org/10.1054/bjoc.1999.0952
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0952